A study demonstrated that RECQL4 inhibition in prostate cancer cells led to significant reduction in invasive growth in vitro and tumorigenic potential in vivo (Su et al., 2010; Mo et al., 2018). This evidence concerns the gene RECQL4 and Familial prostate cancer.